NCT04510090View on ClinicalTrials.gov

Evaluate the Safety, Tolerability, and PK of EP547 in Healthy Subjects and Subjects With Cholestatic or Uremic Pruritus

PHASE1CompletedINTERVENTIONAL
Enrollment

89

Participants

Timeline

Start Date

September 7, 2020

Primary Completion Date

July 8, 2021

Study Completion Date

July 8, 2021

Conditions
PruritusCholestasisKidney Failure
Interventions
DRUG

EP547

EP547

DRUG

Placebo

Placebo

Trial Locations (4)

1010

Auckland Clinical Studies (ACS), Grafton

3004

The Alfred Hospital, Melbourne

3168

Monash Medical Centre, Clayton

5000

CMAX Clinical Research, Adelaide

Sponsors
All Listed Sponsors
collaborator

Novotech (Australia) Pty Limited

INDUSTRY

lead

Escient Pharmaceuticals, Inc

INDUSTRY

NCT04510090 - Evaluate the Safety, Tolerability, and PK of EP547 in Healthy Subjects and Subjects With Cholestatic or Uremic Pruritus | Biotech Hunter | Biotech Hunter